dc.contributor.author | González-Parra, Emilio | |
dc.contributor.author | Herrero, José Antonio | |
dc.contributor.author | Elewa, Usama | |
dc.contributor.author | Bosch, Ricardo J. | |
dc.contributor.author | Ortiz Arduán, Alberto | |
dc.contributor.author | Egido, Jesús | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.date.accessioned | 2014-07-02T12:59:55Z | |
dc.date.available | 2014-07-02T12:59:55Z | |
dc.date.issued | 2013-09-23 | |
dc.identifier.citation | International Journal of Nephrology 2013 (2013): 437857 | es_ES |
dc.identifier.issn | 2090-214X | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/660691 | |
dc.description.abstract | Phenols are uremic toxins of intestinal origin formed by bacteria during protein metabolism. Of these molecules, p-cresol is the most studied and has been associated with renal function impairment and vascular damage. Bisphenol A (BPA) is a molecule with structural similarity with phenols found in plastic food and beverage containers as well as in some dialyzers. BPA is considered an environmental toxicant based on animal and cell culture studies. Japanese authorities recently banned BPA use in baby bottles based on observational association studies in newborns. BPA is excreted in urine and uremic patients present higher serum levels, but there is insufficient evidence to set cut-off levels or to link BPA to any harmful effect in CKD. However, the renal elimination and potential exposure during dialysis warrant the monitoring of BPA exposure and the design of observational studies in which the potential health risks of BPA for end-stage renal disease patients are evaluated. | en_US |
dc.description.sponsorship | This research was supported by a grant from ISCIII and
FEDER funds PS09/00447, Sociedad Española de Nefrologia,
ISCIII-RETICREDinREN/RD06/0016, RD12/0021/,Comunidad
de Madrid/CIFRA/S2010/BMD-2378, and salary support
was from ERA/EDTA to Usama Elewa and Programa
Intensificación Actividad Investigadora (ISCIII/Agencia
Laín-Entralgo/CM) to Alberto Ortiz Arduán. ISC III (PI10/
00072), RECAVA (RD06/0014/0038) and Lilly Foundation
to Jesús Egido. | en_US |
dc.format.extent | 9 pag. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Hindawi | es_ES |
dc.relation.ispartof | International Journal of Nephrology | en_US |
dc.rights | © 2013 Emilio González-Parra et al. | es_ES |
dc.subject.other | Kidney | en_US |
dc.subject.other | Bisphenol A | en_US |
dc.title | Bisphenol A in chronic kidney disease | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1155/2013/437857 | es_ES |
dc.identifier.doi | 10.1155/2013/437857 | es_ES |
dc.identifier.publicationvolume | 2013 | es_ES |
dc.relation.projectID | Comunidad de Madrid. S2010/BMD-2378/CIFRA | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.rights.accessRights | openAccess | en |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD) | |